Appendix 4E and Annual Report

Summary by 6ix AI

The report indicates a decline in revenues from ordinary activities and other income, alongside an increase in the loss attributable to the owners of Syntara Limited. No dividends were declared or paid during the current financial period. The report also highlights significant advancements in Syntara's clinical pipeline, particularly with its lead candidate amsulostat.

Written by 6ix AI from the company’s filing. How 6ix writes summaries